Clinical role of palonosetron in patients receiving cisplatin-containing chemotherapy regimen;Ruolo clinico del palonosetron nei pazienti che ricevono un regime chemioterapico contenente cisplatino

Tumori

Volumn 94, Issue 2, 2008, Pages 23-25

  Labianca, Roberto ^a   Mandalà, Mario ^a   Clerici, Maurizia ^b  

^a OSPEDALI RIUNITI   (Italy)

^b Specialista in Oncologia Medica e in Ematologia   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CARMUSTINE; CHLORMETHINE; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DEXAMETHASONE; DOLASETRON MESILATE; GRANISETRON; ONDANSETRON; PALONOSETRON; STREPTOZOCIN; TROPISETRON;

CANCER CHEMOTHERAPY; COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG RECEPTOR BINDING; GERM CELL TUMOR; HUMAN; NAUSEA AND VOMITING; NEOPLASM; PROPHYLAXIS; TESTIS CARCINOMA;

ANTIEMETICS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; CLINICAL TRIALS AS TOPIC; EVIDENCE-BASED MEDICINE; HUMANS; ISOQUINOLINES; MALE; NAUSEA; QUINUCLIDINES; SEROTONIN ANTAGONISTS; TESTICULAR NEOPLASMS; TREATMENT OUTCOME; VOMITING;

EID: 45249121533     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (4)

1. Grunberg SM, Deuson RR, Mavros P et al: Incidence of chemotherapy-induced nausea and emesis after modern antiemetics. Cancer 2004; 100: 261-268.
2. Aapro M, Grunberg SM, Manikhas GM et al: A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol 2006; 17: 1441-1449.
3. Einhorn LH, Brames MJ, Dreicer R et al: Palonosetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy for germ cell cancer. Support Care Cancer 2007; 15: 1293-300.
4. Grote T, Hajdenberg J, Cartmell A et al: Combination therapy for chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy: palonosetron, dexamethasone, and aprepitant. J Support Oncol 2006; 4: 403-408.